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AbstrACt
Objective To evaluate if a pharmacist-led medication 
review is effective at reducing the anticholinergic/
sedative load, as measured by the Drug Burden Index 
(DBI).
Design Randomised controlled single blind trial.
setting 15 community pharmacies in the Northern 
Netherlands.
Participants 157 community-dwelling patients aged ≥65 
years who used ≥5 medicines for ≥3 months, including at 
least one psycholeptic/psychoanaleptic medication and 
who had a DBI≥1.
Intervention A medication review by the community 
pharmacist in collaboration with the patient’s general 
practitioner and patient.
Primary and secondary outcomes measures The 
primary outcome was the proportion of patients whose 
DBI decreased by at least 0.5. Secondary outcomes were 
the presence of anticholinergic/sedative side effects, falls, 
cognitive function, activities of daily living, quality of life, 
hospital admission and mortality. Data were collected at 
baseline and 3 months follow-up.
results Mean participant age was 75.7 (SD, 6.9) years in 
the intervention arm and 76.6 (SD, 6.7) years in the control 
arm, the majority were female (respectively 69.3% and 
72.0%). Logistic regression analysis showed no difference 
in the proportion of patients with a≥0.5 decrease in 
DBI between intervention arm (17.3%) and control arm 
(15.9%), (OR 1.04, CI 0.47 to 2.64, p=0.927). Intervention 
patients scored higher on the Digit Symbol Substitution 
Test, measure of cognitive function (OR 2.02, CI 1.11 to 
3.67, p=0.021) and reported fewer sedative side effects 
(OR 0.61, CI 0.40 to 0.94, p=0.024) at follow-up. No 
significant difference was found for other secondary 
outcomes.
Conclusions Pharmacist-led medication review as 
currently performed in the Netherlands was not effective 
in reducing the anticholinergic/sedative load, measured 
with the DBI, within the time frame of 3 months. Preventive 
strategies, signalling a rising load and taking action before 
chronic use of anticholinergic/sedative medication is 
established may be more successful.
trial registration number NCT02317666.
bACkgrOunD 
Older people suffer from many medical 
conditions and use more medication than 
any other age group. Multiple medication 
use in combination with age-related physi-
ological changes increase the risk of medi-
cation related harm including adverse drug 
events, drug-drug-interactions and drug-dis-
ease-interactions.1 Medications with anticho-
linergic and/or sedative properties are of 
particular concern in older people, because 
they worsen cognitive impairment and phys-
ical functioning, increase the risk of falls and 
negatively impact activities of daily living, 
hospitalisation and mortality.2 3 Despite 
the risks, these medications are commonly 
prescribed to older individuals.4 5 Different 
measures have been developed to quantify 
the anticholinergic load in patients.6 The 
Drug Burden Index (DBI) determines an 
individual’s exposure to anticholinergic and 
sedative medication taking into account the 
dose.7 8 A high DBI has been associated with 
impairments in both physical and cognitive 
functions among older individuals.9 10 Hence, 
decreasing exposure to anticholinergic and 
strengths and limitations of this study
 ► A successfully completed randomised controlled 
trial, which was the first to focus on changing anti-
cholinergic and sedative load by medication review.
 ► Appropriately powered to detect a clinically relevant 
medium difference.
 ► Showing the effect of ‘real world’ practiced medi-
cation review, rather than the theoretical approach 
described in guidelines.
 ► Three-month follow-up might have been too short to 
detect full effects of medication review, for example, 
due to stepwise reduction of medication, however 
very few dosage changes were seen.
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sedative medication, as measured by the DBI, may have 
important health benefits in older people.
Two small Australian studies suggest that medication 
review could be a promising strategy in reducing the DBI 
in community dwelling older people.11 12 Medication 
review is ‘a structured critical examination of a person’s 
medicines with the objective of reaching an agreement 
with the person about treatment, optimising the impact of 
medicines, minimising the number of medication-related 
problems and reducing waste’.13 While meta-analyses of 
studies in different settings show a lack of effectiveness 
on outcomes such as mortality or hospital (re-)admis-
sions,14–16 these studies included different types of medi-
cation review. Well-structured medication review with 
good cooperation between pharmacist and general prac-
titioner (GP) and involvement of the patient was most 
likely to be successful.17 18 Furthermore fee-for-pharma-
cist-led medication review seemed to have positive health 
benefits on the patient.19 The most effective method 
for medication review remains unknown. Focusing on 
specific subgroups such as older people with multiple 
comorbidities and polypharmacy20 or patients suffering 
from pain21 may be one strategy to optimise medication 
review associated benefits. To date, there is no consensus 
on the effectiveness of medication review as a strategy to 
reduce anticholinergic and sedative load as measured by 
the DBI. Therefore, the primary aim of this study was to 
evaluate if a medication review is an effective strategy to 
reduce anticholinergic and sedative load as measured by 
the DBI. Secondarily, we evaluated the effect of a medi-
cation review on patient outcomes including cognitive 
function, risk of falls, activities of daily living and quality 
of life.
MethODs
study design, setting and participants
We conducted a randomised controlled, single blind trial 
in 15 community pharmacies from December 2014 until 
October 2015 in the Northern Netherlands. Pharmacies 
were recruited via the regional association of pharma-
cists and participation was voluntary. One pharmacist per 
pharmacy was involved in the study. In Dutch community 
pharmacy practice, all registered pharmacists are allowed 
to perform medication reviews. Furthermore, pharma-
cists collaborate with GPs in their area. This includes local 
regular meetings of pharmacists and GPs in pharmaco-
therapy counselling groups.22 In the Netherlands, each 
individual is registered with a single pharmacy.23 Phar-
macies hold a complete electronic medication history for 
each patient registered with them. When undertaking a 
medication review, it is routine practice of pharmacists to 
obtain an extensive summary of the electronic patients’ 
medical records, including latest recorded episodes and 
lab-values, from the GP.24 At the time of the study, all 
Dutch community pharmacists were required to perform 
medication reviews in cooperation with the GP for high-
risk patients according to the guidelines.25 Patients who 
were aged ≥65 years, living independently, using ≥5 medi-
cations for ≥3 months, including at least one psycholeptic 
or psychoanaleptic medication (Anatomic Therapeutic 
Classification (ATC) code N05 or N06)26 and with a 
DBI≥1 were identified by the pharmacist and invited to 
participate in the study. Exclusion criteria were limited 
life expectancy (<3 months), non-Dutch language 
speaker or advanced dementia. Patients who had received 
a medication review within the past 9 months before the 
study period and patients who needed a medication 
review urgently were also excluded. Exclusion criteria 
were identified by the pharmacist with whom the patient 
was registered. The study protocol has been published 
elsewhere.27
randomisation, allocation and blinding
Eligible patients were approached by the pharmacist and 
asked to provide written informed consent. In each phar-
macy, patients willing to participate were then matched in 
pairs by gender, age, DBI and number of medications. One 
patient of each pair was randomly assigned to the inter-
vention condition. All participants gave written consent 
prior to the intervention allocation. The randomisation 
process was conducted by the principal investigator, who 
was not involved in recruitment or data collection. The 
researchers who enrolled the patients and collected the 
data were kept blind to the allocation. Pharmacists and 
patients could not be kept blind, but were explicitly asked 
not to reveal study allocation for individual patients to the 
researchers who collected the data. Therefore, this was a 
single blind study.
Intervention
The intervention was a medication review conducted by 
the community pharmacist in close collaboration with 
the patients’ GP and, if needed, other medical specialists. 
In the Netherlands, medication review consisted of five 
steps.25 Step one was a face-to-face consultation between 
the pharmacist and patient to discuss medication use. 
Second, the pharmacist undertook a pharmacothera-
peutic medication review, identified potential pharma-
cotherapeutic problems taking into account the patient’s 
medical records, including latest recorded episodes and 
lab-values. Accordingly, the pharmacist drafted written 
recommendations for medication optimisation to discuss 
with the patients’ GP. Third, a multidisciplinary meeting 
between pharmacist and GP was held. At this meeting, 
the potential medication problems of the patient were 
discussed and draft of a pharmacotherapeutic action plan 
was decided. Fourth is a discussion of the draft pharma-
cotherapeutic action plan between patient and pharma-
cist and/or GP. The patients’ expectations and wishes 
were key elements in the decision-making process and 
were included in the final action plan. Fifth, a follow-up 
of the final pharmacotherapeutic action plan was under-
taken. Further detail of the medication review process 
and the Dutch guideline underpinning the study can 
be found in our previously published study protocol.27 
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The pharmacists participating in the study all undertook 
regular medication reviews as part of their practice and 
as such were familiar with the guideline. Nonetheless, 
we provided the guidelines to the pharmacists with the 
request to focus on anticholinergic and sedative medica-
tions. No additional educational material on anticholin-
ergic and sedative medication was provided. In order to 
get a reflection of ‘real world’ practice, we let the phar-
macists perform the medication reviews according to 
their routine practice, but we did check whether all five 
steps were conducted. The medication review took place 
within days after the baseline measurement for the inter-
vention patients. In the control arm, patients received the 
medication review after the study period.
Outcomes
The primary outcome was defined as the difference in 
proportion of patients having a decrease of DBI≥0.5 
at 3-month follow-up. We chose a 3-month follow-up 
because this was a reasonable time frame to detect 
medication changes by the medication review. A longer 
follow-up would have increased the chance of medication 
changes due to other reasons, such as changes in disease 
status. Our hypothesis was that the proportion with a 0.5 
decrease in DBI would be higher in the intervention arm 
compared with the control arm. We chose 0.5, as this 
equals the cessation of one drug, which we considered a 
clinically relevant decrease. The DBI was calculated using 
the following formula8:
DBI =  
∑ D
D+ δ 
D=daily dose and δ=minimum recommended daily dose 
were derived for the study from Dutch standard reference 
sources.28 29 Except for sensory and dermatological prepa-
rations, all chronic medications (ie, those used for ≥3 
months) with anticholinergic properties (dry mouth, 
constipation and urine retention) and sedative proper-
ties based on Dutch standard reference sources28–30 were 
included in the calculation. Medication data were derived 
from electronic pharmacy dispensing data and were veri-
fied with the patient.
We included the following secondary outcomes: anti-
cholinergic side effects, measured by the Udvalg for Klin-
iske Undersogelser side effect rating scale,31 sedative side 
effects, derived from a patient-reported adverse drug 
event questionnaire32 and risk of falls, determined by the 
Up&Go test.33 Cognitive function was measured using vali-
dated tests for memory and executive function, namely 
the Seven Minute Screen (7 MS),34 the Trailmaking Test 
A & B35 and Digit Symbol Substitution Test (DSST).36 The 
latter has also previously been used to examine the validity 
of the DBI.8 Activities of daily living were derived using the 
validated Groningen Activity Restriction Scale (GARS)37 38 
and quality of life was measured by the Euroqol-5 Dimen-
sion-3 Level questionnaire, including visual analogue 
scale.39 All tools were administered in Dutch and data 
were collected in a standardised manner, using data 
collection sheets, by researchers who were trained by a 
psychologist. Data collection took place at baseline and 
3-month follow-up for both allocations. Patients with the 
inability to walk were excluded from the Up&Go test and 
the GARS questionnaire. At follow-up, the number of fall 
incidents, hospital admission and mortality were assessed 
based on patient/relative reporting.
sample size calculation
To the best of our knowledge, only one randomised 
pilot study has been conducted assessing the DBI.12 We 
therefore could not calculate the sample size ‘a priori’. 
However, we estimated a sample size based on a power 
of 80% at a significance of 0.05 and an intraclass correla-
tion coefficient up to 0.2 to detect a medium effect size 
on the primary outcome.40 We chose a medium effect 
size as we considered a small effect size to be not clini-
cally relevant and a power to detect a medium effect size 
also to be capable of detecting a large effect size. For this 
calculation, around 160 participants (80 in control arm 
and 80 in intervention arm) were needed. We expected a 
non-response rate of 60% and therefore aimed to invite 
400 patients to participate in the study.
statistical analysis
We performed two analyses. In the first analysis, we 
included all patients with a baseline measurement. In the 
second analysis, we included all patients who were not 
lost to follow-up and who received the intervention as 
allocated. Descriptive statistics were calculated for both 
allocation arms at baseline. For the analysis of the primary 
outcome, we initially considered a generalised linear 
mixed effects model to adjust for dependence of obser-
vations (ie, clustering of patients within pharmacies). 
However, as the intraclass correlation was not significant 
and no significant clustering was observed, extension of 
the model with random effects at the level of pharma-
cies was not necessary. Therefore, only fixed effects were 
considered and standard fixed effects logistic regression 
model applied. Most secondary outcomes were exam-
ined with standard regression models. Variables with a 
skewed distribution were transformed before analysis. 
For dichotomous variables, we reported percentages 
and numbers of patients in the best scoring group, for 
skewed variables we report the median and IQR and for 
normally distributed data, we report the mean and SD. 
Further detail on the analysis of secondary outcome tests 
and questionnaires data can be found in online supple-
mentary appendix table 1. Reported falls, hospitalisa-
tion and mortality were only assessed from patients 
with a follow-up measurement. These variables were 
dichotomised, reported as number and percentages of 
patients and analysed using Fisher’s exact test. A sensi-
tivity analysis was conducted on outliers (online supple-
mentary appendix table 2) and all analyses were adjusted 
for gender, age and number of medication at baseline. 
Secondary outcomes were also adjusted for baseline 
scores. Analyses were done in SPSS 24 and MLwiN 2.36, 
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Missing data
Few data were missing for the primary outcome. Of the 
two patients, who were lost to follow-up, the baseline 
observation for medication use was carried forward to 
follow-up. For eight patients, medication use could not 
be verified with the patient, as they could not be reached 
by telephone despite several attempts. For these patients, 
the medication data from the pharmacy dispensing 
system were used. For secondary outcomes, 5.3% of data 
were missing in the complete dataset, mostly at follow-up 
(4.8%). In the intervention arm, 7.0% of data were 
missing (6.1% at follow-up) across 18 patients, whereas 
in the control arm 3.7% were missing (3.4% at follow-up) 
across 12 patients. In total, 30 patients had missing data, 
of whom two were lost to follow-up. Eight patients were 
not able to complete one or more cognitive tests (0.5% of 
all data). Eleven patients could not be tested at follow-up 
within the study period, six patients due to sickness, four 
patients due to practical reasons (despite numerous 
attempts, we were unsuccessful to arrange an appoint-
ment for the follow-up measurement) and one patient 
had died 2 days before the follow-up appointment. A few 
data were missing for other reasons across nine patients, 
for example patients forgetting their glasses, due to time 
constraints or other reasons.
Missing data in cognitive tests due to inability of the 
patient to complete the task were replaced with the worst 
score for that specific group. Missing data of patients who 
could not be tested at follow-up within the study period 
or who had missing data for other reasons were replaced 
by multiple imputation (five times) in SPSS 24. In this 
paper, we report on the imputed dataset. Sensitivity anal-
ysis showed no difference between the dataset with and 
without missing data.
Patient and public involvement
Patients and or public were not involved in the design or 
conduct of the study. After the study period, all partic-
ipants received a thank you letter including a brief 
summary of the overall results.
results
Participant flow
Overall, 498 patients were approached for participation, 
164 patients provided informed consent (32.9% response 
rate) and 157 patients completed at least the baseline 
measurement and were included in the first analysis 
(figure 1). The dropout rate was 4.3%.
Figure 1 Participant flow. *All patients who had a baseline measurement. †All patients who were not lost to follow-up and 
received the intervention as allocated.
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Participant characteristics
The average participant age was 75.7 (SD, 6.9) years 
in the intervention arm and 76.6 (SD, 6.7) years in the 
control arm, and the majority were female (respectively 
69.3% and 72.0%). Participants in the control arm used 
slightly more medicines at baseline (9.3 (SD, 3.2) to 8.4 
(SD, 2.4)), and more control patients were living with a 
partner (53.6%–44%)%) (table 1).
Primary outcome
In the first analysis, which included all patients with a 
baseline measurement, the proportion of patients with 
a decrease of DBI≥0.5 did not differ between patients 
in intervention arm and control arm (17.3% to 15.9%, 
OR 1.04, CI 0.47 to 2.64, p=0.927). Similar results were 
obtained in the second analysis, which included all 
patients who were not lost to follow-up and who received 
the intervention as allocated (table 2). Descriptive anal-
ysis showed medication changes (starting, stopping, 
dosage change) of DBI medications on ATC code level 
1 in 53.8% of patients from intervention arm and in 
45.0% of patients from control arm. For cardiovascular 
DBI medications, dose increases and dose decreases of 
different medications occurred in 10.8% patients from 
intervention arm compared with 1.3% of patients from 
control arm (online supplementary appendix table 3).
secondary outcome
Secondary outcome tests and questionnaires were anal-
ysed including all patients who were not lost to follow-up 
and who received the intervention as allocated (table 3). 
A difference was seen in the DSST and reporting of seda-
tive side effects between allocation arms. Patients in the 
intervention arm scored higher at follow-up on average 
(3 (SD, 1) to 1 (SD, 0) point (s), OR 2.02, CI 1.11 to 
3.67, p=0.021) and reported less sedative side effects at 
follow-up compared with the control arm (−1 (IQR, −2) 
to 1 (IQR, 0) point(s), OR 0.61, CI 0.40 to 0.94, p=0.024). 
For all other secondary outcomes, no difference was 
found between intervention and control arm.
Table 1 Demographic characteristics at baseline
Intervention (n=75) Control (n=82)
Age (years) mean (SD) 75.7 (6.9) 76.6 (6.7)
Sex (female) (n (%)) 52 (69.3) 59 (72.0)
Number of medicines (mean (SD) 8.4 (2.4) 9.3 (3.2)
DBI (mean (SD) 3.1 (1.0) 3.2 (1.0)
Marital status (n (%)) 
   Partner 33 (44.0) 44 (53.6) 
   Widow/widower/Divorced/single 34 (45.3) 32 (39.0) 
   Unknown 8 (10.6) 6 (7.3) 
Level of education (n (%)) 
   No/low/middle 58 (77.3) 64 (78.0) 
   High 9 (12.0) 13 (15.8) 
   Unknown 8 (10.6) 5 (6.0) 
Medication use at baseline (top 5 (n (%))) 
   ATC nervous system 75 (100) 82 (100) 
   ATC cardiovascular 70 (93.3) 74 (90.2) 
   ATC alimentary tract 64 (85.3) 71 (86.6) 
   ATC blood/blood  forming organs 49 (65.3) 46 (56.1) 
   ATC respiratory tract 20 (26.7) 38 (46.3) 
ATC, Anatomic Therapeutic Classification; DBI, Drug Burden Index.
Table 2 Proportion of patients having a decrease in DBI≥0.5 by analysis type
Analysis type
Proportion with decrease of DBI≥0.5 (%, n)
OR (95% CI)* P values Intervention Control
First analysis (n=157) 17.3 (13) 15.9 (13) 1.04 (0.47 to 2.64) 0.927
Second analysis (n=145) 18.5 (12) 16.3 (13) 1.09 (0.45 to 2.63) 0.857
First analysis: all patients with a baseline measurement.
Second analysis: all patients who were not lost to follow-up and who received the intervention as allocated.
*Binary logistic regression, adjusted for age, gender, number of medication at baseline.
DBI, Drug Burden Index. 
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Reported falls and hospitalisation could be assessed 
from 136 patients who were included in the second anal-
ysis. No significant difference was found in reported 
falls between control arm and intervention arm, respec-
tively, with 15 patients (19.5%) vs 18 patients (30.5%) 
(p=0.100). There was also no difference found between 
control arm and intervention arm in hospitalisation, 
with 9 (11.7%) vs 3 (5.1%) patients reporting unplanned 
hospital admission (p=0.149). Of all patients who were 
included in the study, two died, one (1.2%) in control 
arm and one (1.3%) in intervention arm (p=0.732).
DIsCussIOn
In our study, pharmacist-led medication review did not 
reduce the anticholinergic and/or sedative medication 
load in older people within the first 3 months following 
review. In addition, medication review did not improve 
cognitive function, apart from the DSST. We also found 
that medication review had no effect on anticholinergic 
side effects, quality of life, activities of daily living, risk of 
falls, hospitalisation and mortality. However, intervention 
patients reported fewer sedative side effects.
strengths and limitations of the study
This randomised controlled trial was the first to focus on 
changing anticholinergic and sedative medication load by 
medication review. The trial was completed successfully, 
allocation arms were comparable and we achieved a 
medium response rate. We also believe our study was 
appropriately powered to detect a clinically relevant 
medium difference between intervention and control arm. 
Yet there are some methodological limitations that should 
be considered when interpreting our findings. First, our 
study design might have introduced a risk of contamina-
tion between intervention arm and control arm, as phar-
macists and GPs could have been triggered to optimise 
medication use also for patients in the control arm during 
the study period. We know from the pharmacists that no 
structured medication reviews were performed for control 
patients during the study period. Therefore, we believe 
that changes we observed in control patients were due 
to usual care. Cluster randomisation may have prevented 
the chance of contamination, but this method has other 
disadvantages.41 Second, although we did check whether 
all steps of the medication review were conducted, it was 
outside the scope of our study to investigate to what extent 
pharmacists adhered to methods recommended by the 
guideline on performing the medication review. Informal 
conversations with pharmacists suggested that although 
the guidelines recommend a face-to-face meeting between 
the pharmacist and GP, some pharmacists contacted 
the GP by phone, fax or email due to lack of time. This 
might have had an effect on the implementation of medi-
cation suggestions.18 Furthermore, while as part of the 
Table 3 Secondary outcome tests and questionnaires at follow-up
Outcome
Intervention (n=65) Control (n=80) Treatment difference 
at FU
(95% CI)BL score Δ with FU BL score Δ with FU
Trailmaking Test A, median (IQR) 59.0 (36.9) −8.4 (-4.8) 61.0 (27.8) −6.0 (1.6) −0.01 (−0.11 to 0.09)*
Trailmaking Test B, median (IQR) 149.0 (103.0) −3.9 (24.1) 152.0 (103.0) 1.0 (19.0) −0.01 (−0.14 to 0.11)*
DSST, mean (SD) 36.4 (12.2) 2.6 (1.2) 36.4 (13.2) 1.0 (-0.3) 0.70 (0.11 to 1.30)*† 
7 MS enhanced cued recall, % (n) best 
scoring
85 (55) 0 (0) 84 (71) 5 (4) 0.54 (0.15 to 1.90)‡
7 MS Benton temporal orientation, % 
(n) best scoring
95 (62) −3 (−2) 99 (79) −4 (−3) 1.38 (0.28 to 6.88)‡
7 MS clock drawing, % (n) best scoring 80 (52) −8 (−5) 86 (69) −6 (−5) 0.67 (0.28 to 1.62)‡
7 MS category fluency, mean (SD) 16.1 (5.5) 0.1 (−0.6) 15.9 (5.0) 0.4 (−0.3) −0.18 (−1.55 to 1.20)*
GARS, % (n) best scoring 72 (46) 2 (−1) 69 (54) 0 (0) 1.73 (0.62 to 4.84) ‡§ 
Sedative side effects, median (IQR) 3.0 (5.0) −1.0 (-2.0) 2.0 (4.0) 1 (0) 0.61 (0.40 to 0.94)¶† 
UKU, median (IQR) 17.0 (22.0) −3.0 (1.0) 18.0 (27.0) −1.6 (−2.4) 0.97 (0.67 to 1.39)¶ 
EQ-5D-3L, % (n) best scoring 74 (48) 9 (6) 76 (61) 4 (3) 1.43 (0.51 to 4.03)‡ 
VAS, mean (SD) 6.6 (1.6) −0.2 (0.0) 6.8 (1.4) −0.1 (0.1) −0.09 (−0.50 to 0.32)*
Up&Go, % (n) best scoring 66 (42) 0 (0) 64 (50) 4 (3) 1.37 (0.60 to 3.14)‡§
*Linear regression analysis (reporting unstandardised b).
†Statistically significant difference (p<0.05).
‡Logistic regression analysis (reporting OR).
§Deviation of number of patients: n=64 for intervention, n=78 for control, three patients were excluded from this test/questionnaire.
¶Negative binomial regression analysis (reporting incident rate ratio) used, all adjusted for age, gender, number of medication at baseline.
BL, baseline; FU, follow up, DSST, Digit Symbol Substitution Test; EQ-5D-3L, Euroqol-5 Dimension-3 Level;  GARS, Groningen Activities 
Restriction Scale; UKU, Udvalg for Kliniske Undersogelser (measuring anticholinergic side effects); VAS, visual analogue scale (part of EQ-5D-
3L); 7 MS, seven minute screen.
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established collaboration between pharmacists and GPs in 
Dutch primary care, Dutch pharmacists routinely request 
an extensive summary of the electronic patient’s medical 
records from the GP to perform a medication review, 
it is possible that some pharmacists did not do this. We 
performed a pragmatic trial and therefore our results 
reflect ‘real-world’ practice of how medication reviews 
were carried out in Dutch healthcare practice at the time 
of the study. Third, we followed patients for 3 months after 
the intervention. Possibly, more time may have been neces-
sary to determine the effect of the intervention. We were 
not able to collect data about timing of the medication 
review steps, so in some cases there may have been delay 
in performing all steps. But in Dutch primary care, phar-
macists and GP’s have an established close collaboration 
and therefore we believe that long delays were unlikely. 
Another argument for a longer follow-up could be that 
changes in medication use may require more time, for 
example withdrawing of medication by stepwise reduction 
of dosing. However, there did not seem to be a difference 
in dosage changes between intervention arm and control 
arm. Finally, one-third of all eligible patients were willing to 
participate in the study. Given the frailty of this population 
and the time consuming nature of participation, we think 
this is a very reasonable response rate. Nevertheless, our 
results may not be generalisable to the total population.
Comparison with other studies
The medication changes in both arms were compa-
rable. Small changes in different therapeutic medication 
groups suggest fluctuations of medication use over time 
as prescribing is a dynamic—rather than a static process. 
We do not know the pattern of fluctuations in anticholin-
ergic and sedative medication prescribing; this should be 
explored in longitudinal studies powered to detect changes 
at medication level. Our results are in line with a number of 
meta-analyses, which also reported a lack of effect of medi-
cation reviews on a variety of patient outcomes.14–16 Our 
results are in contrast to a number of studies, which found 
medication reviews to be effective in specific subgroups of 
patients with multiple comorbidities, polypharmacy and 
pain.20 21 The medication reviews in these studies, however, 
were not specifically focusing on medication with anticho-
linergic and/or sedative properties as we did. Two small 
Australian studies suggest that the DBI can be lowered, but 
these studies were based on pharmacist recommendations 
and did not investigate actual implementation of these by 
the GP.11 12 Although some lowering of the DBI was seen, 
the latter study did find that GPs had difficulties in changing 
medications, for example with those medications initiated 
by specialists. A recent study also showed that while it was 
possible to optimise use for a number of medication classes, 
psychotropic medications were among the most difficult to 
adjust.42 So, despite guidance how to reduce anticholinergic 
and sedative medication,43–45 as highlighted by our findings, 
there seem to be important barriers preventing reduction 
in clinical practice.
Conclusion and implications
Using the DBI, a highly vulnerable population group in 
need of medication optimisation can be identified. Phar-
macist-led medication review as currently performed in 
the Netherlands did not appear effective in reducing the 
DBI. While our study was powered to detect a difference 
in medication use, it should be acknowledged that other 
patient outcomes, like geriatric syndromes (eg, risk of falls) 
and adverse events (eg, drug-related hospital admission) 
are very important for the evaluation of medication review 
in older patients. Further studies should ensure sufficient 
sample sizes to study these outcomes.46 47 Despite some prac-
tical issues with the DBI, such as the lack of an international 
consensus-based list of anticholinergic/sedative medication 
including minimum doses,10 we suggest to use the DBI as 
a tool to identify harmful medication users. This depre-
scribing approach may be suitable for other patient groups 
and in other settings such as nursing homes or GP practice 
with colocated pharmacist.4 48–50 Enlarging the multidisci-
plinary team should also be considered, for example psychi-
atrists advising GPs on lowering or ceasing medication and 
psychologists assisting patients during withdrawal. Further-
more, signalling a rising load and taking action before 
chronic use of medication with anticholinergic and/or seda-
tive properties is established may be the preferred approach.
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